IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v16y2019i4p637-d207938.html
   My bibliography  Save this article

Prognostic Factors of Early Stage Epithelial Ovarian Carcinoma

Author

Listed:
  • Shu-Feng Hsieh

    (Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei 100, Taiwan
    Both authors contributed equally.)

  • Hei-Yu Lau

    (Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 111, Taiwan
    Both authors contributed equally.)

  • Hua-Hsi Wu

    (Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 111, Taiwan)

  • Heng-Cheng Hsu

    (Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei 100, Taiwan
    Department of Obstetrics and Gynecology, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu City 300, Taiwan)

  • Nae-Fang Twu

    (Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 111, Taiwan)

  • Wen-Fang Cheng

    (Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei 100, Taiwan
    Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei 100, Taiwan
    Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei 100, Taiwan)

Abstract

We aimed to determine prognostic factors of early stage (I/II) epithelial ovarian carcinoma (EOC) including clinicopathologic and chemotherapeutic regimens. Four hundred and thirty-seven women who underwent primary staging surgery with adjuvant chemotherapy between January 1, 2000 and December 31, 2010 were retrospectively reviewed and analyzed from two medical centers. The prognostic factors were determined from multivariate survival analyses using Cox regression models. The majority of women were diagnosed with stage Ic (244/437, 55.8%). The histopathologic types were clear cell (37.5%), endometrioid (27.2%), serous (14.0%), and mucinous (13.3%). Fifty-seven percent (249/437) of the women received taxane-based (platinum plus paclitaxel) regimens and 43.0% received non-taxane (platinum plus cyclophosphamide) regimens as frontline adjuvant chemotherapy. Clear cell tumors (adjusted Hazard ratio (aHR) 0.37, 95% confidence interval (CI) 0.21–0.73, p = 0.001) showed better 5-year disease-free survival (DFS) than serous tumors. Women diagnosed at FIGO (International Federation of Gynecology and Obstetrics) stage II (aHR 5.97, 95% CI = 2.47–14.39, p < 0.001), grade 3 tumor without clear cell (aHR 2.28, 95% CI = 1.02–5.07, p = 0.004) and who received 3–5 cycles of non-taxane regimens (aHR 3.29, 95% CI = 1.47–7.34, p = 0.004) had worse 5-year overall survival (OS). Clear cell histology treated with taxane-based regimens showed significantly higher 5-year DFS (91.2% vs. 82.0%, aHR = 0.45, 95% CI = 0.21–0.93, p = 0.043) and 5-year OS (93.5% vs. 79.0%, aHR = 0.30, 95% CI = 0.13–0.70, p = 0.005) than those treated with non-taxane-based regimens. We conclude that stage, tumor grade, and chemotherapeutic regimens/cycles are independent prognostic factors for early stage ovarian cancer.

Suggested Citation

  • Shu-Feng Hsieh & Hei-Yu Lau & Hua-Hsi Wu & Heng-Cheng Hsu & Nae-Fang Twu & Wen-Fang Cheng, 2019. "Prognostic Factors of Early Stage Epithelial Ovarian Carcinoma," IJERPH, MDPI, vol. 16(4), pages 1-12, February.
    • Handle: RePEc:gam:jijerp:v:16:y:2019:i:4:p:637-:d:207938
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/16/4/637/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/16/4/637/
    Download Restriction: no
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Chen-Yu Huang & Min Cheng & Na-Rong Lee & Hsin-Yi Huang & Wen-Ling Lee & Wen-Hsun Chang & Peng-Hui Wang, 2020. "Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer," IJERPH, MDPI, vol. 17(7), pages 1-23, March.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:16:y:2019:i:4:p:637-:d:207938. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.